PHARMA NORD ApS: Financial statements 2019
CVR: 67303016
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
PHARMA NORD ApS (CVR 67303016) has filed annual accounts for 2019. In 2019, the company reported revenue of DKK 332,992,000 and a net result of DKK 41,501,000 compared with DKK 37,712,000 the year before. That is a decrease of 0.3% compared with the year before. The profit margin was 12.5%. Equity in the 2019 report amounted to DKK 269,730,000. The solvency ratio was 68.7%. The company had 375 employees in the financial year.
- Revenue
- DKK 332,992,000
- Gross Profit
- DKK 126,143,000
- Profit/Loss
- DKK 41,501,000
- Equity
- DKK 269,730,000
- Total Assets
- DKK 392,558,000
- Employees
- 375
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | 333 mio. | 126.1 mio. | 41.5 mio. | 269.7 mio. | 375 |
| 2018 | 334 mio. | 132.3 mio. | 37.7 mio. | 212.7 mio. | 364 |
| 2017 | 343.1 mio. | 135.4 mio. | 46.8 mio. | 181.9 mio. | 378 |
| 2016 | 337.3 mio. | 149.4 mio. | 62 mio. | 142 mio. | 315 |
| 2015 | 417.5 mio. | 198.7 mio. | 55.8 mio. | - | 307 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
PHARMA NORD ApS has published its annual report for 2018. Revenue came to DKK 333,989,000, and the net result was DKK 37,712,000.
About PHARMA NORD ApS
PHARMA NORD ApS is a Danish company of the type Anpartsselskab based in Vojens, founded in 1981. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named DANMARKS HELSEKOST DISTRIBUTION ApS. The management consists of Eli Wallin. The board consists of Michael Christiani Havemann (chair) and Eli Wallin. The company is owned by PHARMCO I ApS and PharmCo III ApS. The company has 298 employees (2026). In 2025, the company reported revenue of DKK 518,005,000 and a net result of DKK 26,711,000 compared with DKK 32,254,000 the year before. Equity in the 2025 report amounted to DKK 181,417,000.